Thursday, 22 January 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 22 January 2026
News

Spot-the-difference logo stoush

Posted 22 January 2026 AM

Merck has failed in its bid to block a trademark application by Pfizer, after arguing it should be rejected due to visual similarities with one of its own trade marks.

The German drugmaker had challenged the trademark for Pfizer's RSV vaccine injection Abrysvo, arguing it was visually similar to the trademark for Merck's MS pill Mavenclad. Both trade marks have a bi-colour circular feature to the left of the name of the drug.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.